CN102836228B - Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof - Google Patents
Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof Download PDFInfo
- Publication number
- CN102836228B CN102836228B CN201210380257.5A CN201210380257A CN102836228B CN 102836228 B CN102836228 B CN 102836228B CN 201210380257 A CN201210380257 A CN 201210380257A CN 102836228 B CN102836228 B CN 102836228B
- Authority
- CN
- China
- Prior art keywords
- parts
- conjunctivitis
- chinese medicine
- radix
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal composition for treating conjunctivitis, belonging to the technical field of Chinese medicines. The Chinese medicinal composition is prepared from 15 parts of baikal skullcap root, 6 parts of honeysuckle flower, 10 parts of divaricate saposhnikovia root, 10 parts of virgate wormwood herb, 10 parts of szechuan lovage rhizome, 20 parts of dandelion, 20 parts of cicada shell, 10 parts of gentian, 5 parts of white paeony root, 5 parts of mint and 10 parts of liquoric root. The Chinese medicinal composition has good treatment effects on the aspect of treatment of inflammatory conjunctivitis, bacterial conjunctivitis, viral conjunctivitis and allergic conjunctivitis, and has a remarkable clinical popularization value.
Description
Technical field
The invention belongs to Chinese medicine technical field, be specifically related to a kind of Chinese medicine composition for the treatment of conjunctivitis.
Background technology
Conjunctivitis (conjunctivitis) is the commonly encountered diseases of ophthalmology, the general designation of the inflammatory reaction that to be conjunctival tissue occur in the effect of extraneous and body oneself factor.Because most of conjunctiva directly contacts with extraneous, therefore be easily subject in surrounding the stimulation of infectious (as antibacterial, virus and chlamydia etc.) and non-infectious factor (wound, chemical substance and physical factor etc.), and the blood vessel of conjunctiva and lymphoid tissue are abundant, self and extraneous antigen easily make its sensitization.
Although the sickness rate of conjunctivitis is not yet definite at present, whenever Xia Qiu carrys out to be beneficial to because weather is damp and hot bacterial reproduction temporarily, primary disease is the interior outbreak of epidemic of certain limit very easily.Particularly some coastal cities, are beneficial to a lot of people of bacterial reproduction and can suffer from acute conjunctivitis because weather is damp and hot.During due to this onste, have photophobia, shed tears, twinge and have thin secretions, eyelid swelled simultaneously, eye conjunctiva is because of the blood vessel of expansion and hemorrhagely make it to become redness.Hurried the breaking with tremendous force of its onset having a strong impact on people's Working Life, as treated and also can change into chronic conjunctivitis not in time.Although conjunctivitis itself is general and not serious to eyesight influence, in the time that its inflammation involves cornea or leads to complications, can cause the infringement of vision.
Generally adopt antimicrobial ointment or eye drip medicine to treat for infectious acute conjunctivitis clinically at present; symptom can be eliminated in 1 week to 6 weeks after medication conventionally; but in therapeutic process, the relapse rate of conjunctivitis is higher; and eye drop can cause a large amount of volatilizations of tear easily to cause xerophthalmia while use, is having a strong impact on patient's work and life.Clinically for season anaphylaxis conjunctivitis treatment conventionally adopt eye drop eye drip to merge to take Claritin and treat, and obtain good clinical short-term curative effects, but because these Western medicine mostly have potential hepatotoxicity, and action target spot is single, long-term taking can affect patient's health status.Therefore researching and developing the effective medicine of a kind of conjunctivitis is of great practical significance.
The history of Chinese medicine conjunctivitis is of long standing and well established, and as an importance of modern oculopathy Comprehensive Treatment, more and more receives publicity in recent years.Zhang Yanli uses and moves back red collyrium and rinse conjunctival sac treatment acute conjunctivitis and obtained good clinical therapeutic efficacy in " Chinese medicine moves back the observation of curative effect of red collyrium to acute conjunctivitis ".Wu Qingbo discloses a kind of Chinese medicine compound (Herba Schizonepetae 10g, art thief 10g, Flos Chrysanthemi Indici 12g in " Functional observation of herbal fumigation in treatment vernal conjunctivitis ", Periostracum Cicadae 10 g, Fructus Kochiae 10g, Fructus Atriplicis Sibiricae 10g, Radix Aconiti Preparata 3 g, Herba Asari 3g ， Herba Siegesbeckiae 15g, Radix Sophorae Flavescentis 10g, Zaocys l0 g, Radix Platycodonis 10g, Semen Armeniacae Amarum 10g, Cortex Dictamni 12g, Radix Glycyrrhizae 12g), after this medicine is first smoked, clothes can have to vernal conjunctivitis the effect for the treatment of and prevention of recurrence.
Make a general survey of the research direction of world's new drug, be mainly single chemicals and preparations thereof of research and development the eighties in the past, starts to develop biotechnology and natural medicinal plants after the eighties, and drug research direction is tending towards multiformity.In conjunction with modern Chinese medicine theory of development, from improving the angle of curative effect of medication, reduction side effect, through Chinese medicine ingredients being screened to the preparation that extraction and/or compatibility make, its side effect is little, safe, has the advantage that chemical synthetic drug can not be compared.
Summary of the invention
For the deficiency of current conjunctivitis clinical treatment medicine, first object of the present invention is to provide a kind of Chinese medicine composition for the treatment of conjunctivitis, and this Chinese medicine composition has good therapeutic effect aspect the struvite conjunctivitis for the treatment of, bacterial conjunctivitis, viral conjunctivitis and anaphylaxis conjunctivitis.
The present invention treats the Chinese medicine composition of conjunctivitis, raw material by following weight portion makes: 15 parts of Radix Scutellariaes, 6 parts of Flos Loniceraes, 10 parts of Radix Saposhnikoviaes, 10 parts of Herba Artemisiae Scopariaes, 10 parts of Rhizoma Chuanxiongs, 20 parts of Herba Taraxacis, 20 parts of Periostracum Cicadaes, 10 parts of Radix Gentianaes, 5 parts of the Radix Paeoniae Albas, 5 parts of Herba Menthaes, 10 parts, Radix Glycyrrhizae.
Radix Scutellariae another name Radix Scutellariae, tsuchikane tea root, be labiate, is used as medicine with root.Have heat clearing and damp drying, removing heat from blood is antiabortive, detoxicating functions.Cure mainly the diseases such as epidemic febrile disease, upper respiratory tract infection, cough due to lung-heat, damp and hot jaundice, pneumonia, dysentery, hemoptysis, conjunctival congestion, frequent fetal movement, hypertension, carbuncle furuncle.
Flos Lonicerae is Caprifoliaceae woodbine Radix Ophiopogonis and congener dry flower or the first flower of opening of band.Flos Lonicerae is described as the good medicine of heat-clearing and toxic substances removing from ancient times.The sweet cold fragrance of its property, clearing away heat with drugs sweet in flavor and cold in nature and not injuring one's stomach, fragrance thoroughly reaches and can be eliminating evil.Flos Lonicerae can dispelling wind-heat, also kind removing summer-heat blood poison, and for various febrile diseases, as fever of the body, dermexanthesis, send out the cards such as speckle, pyretic toxicity carbuncle sore, laryngopharynx swelling and pain, all effect is remarkable.Modern medicine shows, Flos Lonicerae is containing cyclohexanhexanol, flavonoid, inositol, Saponin and tannin etc., there is broad-spectrum antibacterial action, the various pathogens such as staphylococcus aureus, dysentery bacterium is all had to stronger inhibitory action, the multiple pathogenic microorganisms such as leptospira, influenza virus and pathogenic moulds are also had to inhibitory action.In addition, Flos Lonicerae also has obvious antiinflammatory and refrigeration function, and Flos Lonicerae water and steeping in wine liquid have obvious lethal effect to tentative tumor cell.
Radix Saposhnikoviae is the root of Umbelliferae herbaceos perennial Radix Saposhnikoviae, main product in Heilungkiang, the ground such as Sichuan, the Inner Mongol.Its acrid in the mouth, sweet, slightly warm in nature.Return bladder, liver, spleen channel; There is effect that expelling pathogenic wind from the body surface, removing dampness to relieve pain, relieving convulsion are jerked surely.Cure mainly expelling pathogenic wind from the body surface; Removing dampness to relieve pain; Spasmolytic; Antipruritic.Main affection of exogenous wind-cold; Headache general pain; Rheumatic arthralgia; Joint is ached; Stomachache is had loose bowels; Discharging fresh blood stool; Tetanus; Rubella pruritus; Skin infection from the beginning of.For headache due to common cold, rheumatic arthralgia, rubella pruritus, the diseases such as tetanus
Herba Artemisiae Scopariae has effect of clearing away heat-damp and promoting diuresis, jaundice eliminating, cures mainly the diseases such as jaundice, dysuria, eczema pruritus, infectious jaundice type hepatitis.Modern pharmacology research Herba Artemisiae Scopariae has function of gallbladder promoting, the effects such as liver function protecting, antipyretic, antiinflammatory, blood fat reducing, blood pressure lowering, coronary dilating.
The pungent temperature of Rhizoma Chuanxiong is fragrant dry, walks and does not keep, can go loose, the up top, mountain peak that reaches; Enter again blood system, the descending sea of blood that reaches.Blood circulation promoting and blood stasis dispelling effect is extensive, the various diseases of suitable stagnation of blood stasis; Wind-expelling pain-stopping, effectiveness is excellent, can control the diseases such as wind syndrome of head headache, rheumatic arthralgia.
Dandelion Compositae herbaceos perennial.In Herba Taraxaci plant, contain the multiple health-nutrition compositions such as taraxol, taraxacin, choline, organic acid, inulin, have the effects such as diuresis, cathartic, jaundice eliminating subcutaneous ulcer, function of gallbladder promoting.Record according to Compendium of Material Medica, the flat sweet and slightly bitter taste of its property, has heat-clearing and toxic substances removing, dispersing swelling and dissipating binds and galgctogogue action, very effective to treatment mastitis.No matter decoct juice oral, or smash to mud external application, effect all had.In addition, Herba Taraxaci also has the effects such as diuresis, cathartic, jaundice eliminating subcutaneous ulcer, function of gallbladder promoting, is widely used in clinical.
Periostracum Cicadae has dispelling wind and heat pathogens effect, often coordinates Herba Menthae to be equal to use for wind heat table disease; Rubella pruritus is also had to the function of dispelling wind for relieving itching.Clinically cure mainly loose wind heat, lung qi dispersing, determines convulsion.Control affection due to external wind and heat, cough hoarseness, measles is sent out not smooth thoroughly, rubella pruritus, pediatric epilepsy scared, conjunctival congestion, cataracta, furuncle swelling toxin, the diseases such as tetanus.Modern medicine proves that Periostracum Cicadae has extensive inhibition usefulness to cental system, and has stronger immunosuppressant and anti-allergic effects.
Radix Gentianae bitter in the mouth, cold in nature.Return liver, gallbladder meridian.The clinical heat clearing and damp drying that cures mainly; Eliminating pathogen in the liver arresting convulsion.Jaundice due to damp-heat; Urine leaching pain; Swelling of the vulva pudendal pruritus; Damp-heat vaginal discharge; The feeling of fullness in the head headache of liver and gall excess-fire; Conjunctival congestion and swelling pain; Deaf ear is swollen; Hypochondriac pain bitter taste; The diseases such as convulsion with spasms.Modern pharmacology confirms the multiple pharmacologically actives such as Radix Gentianae has hepatic cholagogic, and diuresis is antibacterial.
The Radix Paeoniae Alba enters liver, spleen channel, has nourishing blood to suppress the hyperactive liver, slow middle pain relieving, and yin fluid astringing is received effect of antiperspirant.Cure mainly the breast abdomen pain over the hypochondriac region, dysentery stomachache, spontaneous sweating, fever due to yin deficiency, menoxenia, metrorrhagia, is with inferior disease.Herba Menthae is one of Chinese conventional Chinese medicine.It is pungent cool property sweating antipyretic medicine, controls influenza, headache, conjunctival congestion, fever of the body, throat, the dental bed disease such as swell and ache.External can training the mind dysmenorrhoea, skin pruritus, erythra and eczema etc.The Herba Menthae of light friend Greenhouse Fruit Picking is again the fresh vegetable on dining table in the Spring Festival.Clearly good to eat.Usually with Herba Menthae for tea, improving eyesight clears away heart-fire.Modern medicine proves that Herba Menthae has very strong antiviral and antibacterial activity, and has certain antiallergic activity.
In Chinese medicine composition of the present invention, Radix Scutellariae and Flos Lonicerae can play the cooperative effect of dispelling phlegm and eliminating dampness, removing pathogenic heat from blood and toxic substance from the body.Radix Saposhnikoviae and Rhizoma Chuanxiong can blood circulation promoting and blood stasis dispelling, removing mass dredging collateral; Herba Artemisiae Scopariae, Periostracum Cicadae, Herba Menthae and Herba Taraxaci share can clearing away heat-damp and promoting diuresis, dispelling wind and heat pathogens, dispersing swelling and dissipating binds symptom.Rhizoma Chuanxiong and Radix Scutellariae can heat clearing and damp drying, eliminating stagnation is induced sweat.The Radix Paeoniae Alba and Radix Gentianae can nourishing blood to suppress the hyperactive liver, nourishing blood to tranquillize the mind.Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription.All medicines share, and play altogether effect of dispersing swelling and dissipating binds, activating blood circulation to dissipate blood stasis, dispelling phlegm and eliminating dampness.
The method of preparing Chinese medicine composition of the present invention is as follows: get each medical material of above-mentioned components by weight percent, add the water of 5-15 times of medical material gross weight, soak 10-60 minute, decoct 1-4 time, each 1-3 hour, filters, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.05-1.25, and this relative density is the testing result under 60 degrees Celsius, and adding ethanol is 60-90%(v/v to containing alcohol amount), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, to obtain final product.
The above-mentioned Chinese medicine composition of the present invention can further be prepared into conventional clinically pharmaceutical preparation, is preferably mixture, tablet, capsule.
The present invention also discloses a kind of purposes of above-mentioned Chinese medicine composition, i.e. the purposes of above-mentioned Chinese medicine composition in preparation treatment conjunctivitis medicine.Wherein said conjunctivitis can be simple struvite conjunctivitis, viral conjunctivitis, bacterial conjunctivitis or anaphylaxis conjunctivitis.The embodiment of the present invention 4 confirms that by the antiinflammatory action of investigating Chinese medicine composition xylol induced mice inflammatory model of the present invention Chinese medicine composition provided by the invention can have significant anti-inflammatory efficacy, its antiphlogistic effects is better than hydrocortisone, wherein the antiphlogistic effects of high dose group and middle dosage group have compared with hydrocortisone significant difference (
p< 0.05), when this shows the struvite conjunctivitis of traditional Chinese medicine composition for treating of the present invention, act on comprehensively, there is obvious synergism, obtain unforeseeable curative effect of medication.The embodiment of the present invention 5 finds that to common pathogen fungistatic effect Chinese medicine composition of the present invention can play inhibition to most pathogenic bacterium under very low crude drug concentration by investigating Chinese medicine composition of the present invention, and this has has a broad antifungal spectrum, treatment advantage that antibacterial concentration is low while showing the present invention for the treatment of bacterial conjunctivitis.The embodiment of the present invention 6, by investigating the clinical therapeutic efficacy of Chinese medicine composition of the present invention to viral conjunctivitis patient, finds that Chinese medicine composition medication of the present invention can obviously improve the symptom of popular hemorrhagic conjunctivitis after 5 days, and patient's cure rate is high.The embodiment of the present invention 7 has been investigated the therapeutic effect of Chinese medicine composition of the present invention to anaphylaxis conjunctivitis, find that Chinese medicine composition of the present invention can alleviate anaphylaxis conjunctivitis symptom, its total effective rate for anaphylaxis conjunctivitis is significantly higher than the agent of common drug Cetirizine hydrochloride Tablets.
In a word, the present invention compared with prior art, has the activity of fine treatment conjunctivitis, and the present invention is pure Chinese medicinal preparation, to human body particularly to liver avirulence.When the present invention uses as conjunctivitis medicine, drug effect is comprehensive, in dispersing the stagnated live-QI to relieve the stagnation of QI, spleen invigorating food stagnation removing, can also obtain effect of activating blood circulation to dissipate blood stasis, dispelling phlegm and eliminating dampness, can make rapidly conjunctivitis conditions of patients take a turn for the better; And Chinese medicine composition preparation of the present invention is simple, and substantially nontoxic, raw material is easy to get, and is suitable for popular use, has good potential applicability in clinical practice.
Detailed description of the invention
Further describe the present invention by detailed description of the invention below, but the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, Chinese medicine composition of the present invention is suitably improved, replaces the component that effect is identical, within will become apparent to those skilled in the art that they are all deemed to be included in scope of the present invention.
part I, the preparation of Chinese medicine composition of the present invention
embodiment 1 Chinese medicine composition mixture of the present invention
Prescription: 15 parts of Radix Scutellariaes, 6 parts of Flos Loniceraes, 10 parts of Radix Saposhnikoviaes, 10 parts of Herba Artemisiae Scopariaes, 10 parts of Rhizoma Chuanxiongs, 20 parts of Herba Taraxacis, 20 parts of Periostracum Cicadaes, 10 parts of Radix Gentianaes, 5 parts of the Radix Paeoniae Albas, 5 parts of Herba Menthaes, 10 parts, Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add the water of 5 times of medical material gross weight, soak 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.1, and this relative density is the testing result under 60 degrees Celsius, adding ethanol is 75%(v/v to containing alcohol amount), leave standstill 24 hours, get supernatant, recovery ethanol is concentrated, adds water to 1000ml, stirs evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
embodiment 2 Chinese medicine composition tablet of the present invention
Prescription: 15 parts of Radix Scutellariaes, 6 parts of Flos Loniceraes, 10 parts of Radix Saposhnikoviaes, 10 parts of Herba Artemisiae Scopariaes, 10 parts of Rhizoma Chuanxiongs, 20 parts of Herba Taraxacis, 20 parts of Periostracum Cicadaes, 10 parts of Radix Gentianaes, 5 parts of the Radix Paeoniae Albas, 5 parts of Herba Menthaes, 10 parts, Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add the water of 10 times of medical material gross weight, soak 60 minutes, decoct 1 time, each 1 hour, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.25, and this relative density is the testing result under 60 degrees Celsius, adding ethanol is 80%(v/v to containing alcohol amount), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulation, tabletting and get final product.
embodiment 3 Chinese medicinal composition capsules of the present invention
Prescription: 15 parts of Radix Scutellariaes, 6 parts of Flos Loniceraes, 10 parts of Radix Saposhnikoviaes, 10 parts of Herba Artemisiae Scopariaes, 10 parts of Rhizoma Chuanxiongs, 20 parts of Herba Taraxacis, 20 parts of Periostracum Cicadaes, 10 parts of Radix Gentianaes, 5 parts of the Radix Paeoniae Albas, 5 parts of Herba Menthaes, 10 parts, Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add the water of 8 times of medical material gross weight, soak 45 minutes, decoct 4 times, each 1.5 hours, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.2, and this relative density is the testing result under 60 degrees Celsius, adding ethanol is 90%(v/v to containing alcohol amount), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated and get final product.
part II, the pharmacodynamics of Chinese medicine composition of the present invention is investigated
the antiinflammatory action of embodiment 4 Chinese medicine composition xylol of the present invention induced mice inflammatory model
Hydrocortisone is that synthetic is also naturally occurring glucocorticoid, and hydrocortisone enters after cell, activates cytoplasmic receptor, after allosteric, enter nucleus, be combined with DNA response element, cause inhibition or the induction of genetic transcription, the expression of inflammation associated protein is changed.Hydrocortisone has stronger anti-inflammatory activity, is usually used in clinically the treatment of arthritis, conjunctivitis.
, experimental technique:
50 KM mices, male and female half and half, body weight 25-30 gram, be divided at random 5 groups by body weight, i.e. dosage group in model control group, combination group high dose group, compositions, compositions low dose group, positive controls, every group 10, each administration group mice gives respectively following medicine:
Model control group: gavage gives the normal saline of same volume;
Positive controls: gavage gives the hydrocortisone drug solution of 5mg/kg;
Compositions high dose group: gavage gives 50mg/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition is by crude drug amount;
Dosage group in compositions: gavage gives 20 mg/kg embodiment 1 Chinese medicine compositions, and Chinese medicine composition is by crude drug amount;
Compositions low dose group: gavage gives 5 mg/kg embodiment 1 Chinese medicine compositions, and Chinese medicine composition is by crude drug amount;
Each administration group is administered once every day, successive administration 7d.After last administration, get dimethylbenzene 20 μ l, be applied to each mouse right ear.After 30 minutes, get and be respectively subject to reagent 0.03 ml to be evenly applied to respectively mouse right ear, auris dextra is put to death after 3.5 hours to dimethylbenzene, measures the each group of mice left and right ear method of double differences.Ear method of double differences assay method: place cuts two ears along auricle baseline, lays auricle with 8mm card punch at the same position of left and right ear, weighs, and the ear method of double differences=auris dextra sheet weight-left auricle weight.The ear method of double differences can be used as evaluates antiinflammatory index.
experimental result:measure each experimental mice ear method of double differences and evaluate the antiphlogistic effects of each medication group medicine.Measurement result is in table 2.
The comparison of the each experimental mice ear of table 1 method of double differences
| Group | n | The ear method of double differences (mg) |
| Model control group | 10 | 8.20±1.18 |
| Positive controls | 10 | 6.24±1.51 * |
| Compositions high dose group | 10 | 2.81±1.84 **## |
| Dosage group in compositions | 10 | 4.45±1.54 **# |
| Compositions low dose group | 10 | 5.93±1.24 * |
With model control group comparison,
* p< 0.05; With model control group comparison,
* p< 0.01;
With positive controls comparison,
# p< 0.05; With positive controls comparison,
## p< 0.01.
Result demonstration gives positive drug and Chinese medicine composition of the present invention all can be obtained significant antiphlogistic effects, wherein the antiphlogistic effects of Chinese medicine composition high dose group of the present invention and positive controls have utmost point significant difference, Chinese medicine composition low dose group and positive controls have significant difference, and this shows that the high dose group of Chinese medicine composition of the present invention and the antiphlogistic effects of low dose group will significantly be better than positive controls.
the In Vitro Bacteriostasis experiment of embodiment 5 Chinese medicine compositions of the present invention
The strain that this experiment is used and culture medium are respectively α-hemolytic streptococcus (32209), beta hemolytic streptococcus (32210), colon bacillus (44102), proteus vulgaris (49101), Salmonella paratyphi A (50001), shigella dysenteriae (51252), staphylococcus aureus [26111 (5)], hemophilus influenza (58529-4), nutrient agar (in tired pharmaceutical biological product calibrating institute); Opacity tube (Chinese bacterial turbidity standard, the biological combinations calibrating of Chinese medicine institute).
In Vitro Bacteriostasis experiment: 1. prepare pastille agar plate.Tested material is pressed to the culture medium of doubling dilution preparation different pharmaceutical concentration, heating, modulation required pH value separately, 121 DEG C of sterilizing 30 min, are chilled to 45 DEG C.Pour into into aseptic flat board (plate d=
65 mm, 10 ml/ plates), finally make the extension rate containing tested material stock solution (2g/ml) in culture medium be respectively l:2,1:4 ... 1:1024.Do blank culture medium separately simultaneously.2. inoculation.Get the bacterium in young age that reaches the third generation, point
Be not the bacterium liquid to be checked of 108 cfu/ml with 0.9% sodium chloride solution by standard opacity tube corrected concentrations, be inoculated in respectively the agar surface of pastille separately of different doubling dilutions, inoculate parallel point 3 points simultaneously, make at every containing 2 one bacterium liquid.The liquid-drop diameter of each vaccination is 5-8 mm.After vaccination is dry, upset is dull and stereotyped cultivates 20 h observed results (simultaneously doing blank) in 36 DEG C of constant incubators.3. criterion.Not occur that minimum dilution tested material concentration on the agar plate of bacterium colony is as its minimum inhibitory concentration (MIC).
In this experiment, Chinese medicine composition is as shown in table 2 to the minimal inhibitory concentration of each pathogenic strain:
The minimal inhibitory concentration of table 2 Chinese medicine composition of the present invention to each pathogenic strain
| Bacterial strain | Minimal inhibitory concentration (MIC, g/ml) | Drug dilution degree |
| α-hemolytic streptococcus | 0.008 | 1：256 |
| Beta hemolytic streptococcus | 0.016 | 1：128 |
| Escherichia coli | 0.032 | 1：64 |
| Proteus vulgaris | 0.016 | 1：128 |
| Salmonella paratyphi A | 0.032 | 1：64 |
| Shigella dysenteriae | 0.064 | 1：32 |
| Hemophilus influenza | 0.016 | 1：128 |
| Staphylococcus aureus | 0.032 | 1：64 |
Result demonstration, Chinese medicine composition of the present invention all has good fungistatic effect to most pathogenic bacterium, and this,, for being the most easily subject to the extraneous eyes conjunctiva infecting, has very important treatment meaning.
the clinical therapeutic efficacy of embodiment 6 Chinese medicine composition of the present invention to viral conjunctivitis
Epidemic hemorrhagic conjunctivitis is the infectiousness oculopathy that belongs to outbreak of epidemic being caused by a kind of novel pico+ribonucleic acid+virus, and this disease morbidity is anxious, and infectiousness is strong, the western medicine poor effect using clinically at present.
1 clinical data
This group is observed case 50 examples, wherein male's 38 examples, and women's 12 examples, 32 years old mean age, are eyes morbidity.The diagnostic criteria of hemorrhagic conjunctivitis is: patient's eyes successively or occur puckery pain, open, the upper gluing closure of lower eyelid when rise morning by photophobia difficulty simultaneously.Eyelid swelled when examination of eyes, conjunctival congestion, some lamellar is hemorrhage, and there is pseudomembrane in patient's conjunctiva, angle damage on cornea, fluorescence staining is point-like or slice colouring.
2 Therapeutic Method
For oral administration from intending conjunctivitis mixture.Prescription: 15 grams of Radix Scutellariaes, 6 grams of Flos Loniceraes, 10 grams of Radix Saposhnikoviaes, 10 grams of Herba Artemisiae Scopariaes, 10 grams of Rhizoma Chuanxiongs, 20 grams of Herba Taraxacis, 20 grams of Periostracum Cicadaes, 10 grams of Radix Gentianaes, 5 grams of the Radix Paeoniae Albas, 5 grams of Herba Menthaes, 10 grams, Radix Glycyrrhizae.Be decocted in water for oral dose, 1 dose of every day, 2 times/d, successive administration 5 days.
3 therapeutic effect
In therapeutic process, judge the therapeutic effect of medicine to hemorrhagic conjunctivitis.The curative effect judging standard using is:
A) recovery from illness: ophthalmalgia disappears, and without sensation of dryness, without gum adacrya, sheds tears without photophobia.Check: eyelid is without swelling, and conjunctiva is without hyperemia, without pseudomembrane and hemorrhage, corneal transparency.
B) take a turn for the better: ophthalmalgia disappears, and sheds tears without photophobia, has sensation of dryness.Check: eyelid is without swelling conjunctival congestion but without pseudomembrane, corneal transparency.
Chinese medicine composition of the present invention is presented at 50 routine hemorrhagic conjunctivitis patient's medications after 5 days to the therapeutic effect of hemorrhagic conjunctivitis, and recovery from illness or improvement all appear in patient's the state of an illness, and 41 examples of wherein fully recovering, account for 82 %; 9 examples that take a turn for the better, account for 18 %.This shows that Chinese medicine composition of the present invention has significant therapeutic effect at tool aspect treatment hemorrhagic conjunctivitis.
the therapeutical effect of embodiment 7 Chinese medicine composition of the present invention to anaphylaxis conjunctivitis
Anaphylaxis conjunctivitis is a para-immunity disease, conventionally has obvious ophthalmic pruritus, conjunctival congestion, papillary hypertrophy and follicle hypertrophy, and corneal has no significant effect more, and the longer sings and symptoms of the course of disease is heavier.Treatment anaphylaxis conjunctivitis is taking eye local application as main, and main purpose is mitigation symptoms and avoids occurring sequela.Antihistaminic, vasoconstrictor, mast cell stabilizers, NSAID (non-steroidal anti-inflammatory drug), glucocorticoid etc. are the common drug of topical therapeutic anaphylaxis conjunctivitis in recent years.
1 clinical data
1) inclusive criteria
Seasonal allergic conjunctivitis is except seasonality outbreak and symptom, somatic feature score are all relatively low, and other clinical characters and perennial allergic conjunctivitis are quite similar, so include in both are unified.Diagnosis is main with reference to " Chinese ophthalmology " (1) symptom: ophthalmic pruritus, shed tears, burning sensation, foreign body sensation, photophobia and secretions increases (mostly being mucus).(2) sign: conjunctival congestion, edema, palpebral conjunctiva nipple follicle hypertrophy.
2) exclusion standard
With eye patients such as keratitis, xerophthalmia, glaucomas; The person that executes ophthalmologic operation in nearly 1 month; Use may affect the patient of other hydryllin, mast cell stabilizers and corticosteroid collyrium, nasal mist or the systemic drug of result of study; Intentionally, the patient of the serious primary disease such as brain, liver, kidney and hemopoietic system; Not medication in accordance with regulations, cannot judge the infull person of curative effect or data.
3) physical data
Meet seasonal allergic conjunctivitis 66 example and perennial allergic conjunctivitis 24 examples totally 90 examples of above-mentioned standard through making a definite diagnosis.Make a definite diagnosis the random method of rear employing district group clients is divided into two groups: treatment group 45 examples, male 19 examples, female's 26 examples; Age 19-66 year (average 36.2 years old).Matched group 45 examples, male 21 examples, female's 24 examples; Age 17-65 year (average 35.8 years old).Two groups of physical data are learned processing by statistics, and difference not statistically significant (P>0.05), has comparability.
2 Therapeutic Method
For oral administration from intending conjunctivitis mixture.Prescription: 15 grams of Radix Scutellariaes, 6 grams of Flos Loniceraes, 10 grams of Radix Saposhnikoviaes, 10 grams of Herba Artemisiae Scopariaes, 10 grams of Rhizoma Chuanxiongs, 20 grams of Herba Taraxacis, 20 grams of Periostracum Cicadaes, 10 grams of Radix Gentianaes, 5 grams of the Radix Paeoniae Albas, 5 grams of Herba Menthaes, 10 grams, Radix Glycyrrhizae.Be decocted in water for oral dose, 1 dose of every day, 2 times/d, successive administration 5 days.Matched group is taken Cetirizine hydrochloride Tablets agent (Lunan Beite Pharmaceutical Co., Ltd. produces, 10mg/ sheet, a slice on the one).After treatment latter 3 days, 5 days, 7 days and drug withdrawal, within 1 week, check and follow up a case by regular visits to respectively, record eye subjective symptom and slit lamp examination palpebra inferior, conjunctiva, cornea.
3, therapeutic effect
Curative effect determinate standard: adopt " clinical characters of anaphylaxis conjunctivitis ".Symptom and sign standards of grading evaluation index: ophthalmic pruritus, shed tears, foreign body sensation, eyelid nipple, palpebral follicles, secretions, conjunctival congestion, chemosis.And calculate symptom integral.Computing formula: total mark × 100% before total mark decline index=(the rear total mark of total mark-treatment before treatment)/treatment.Effective: integration reduces >70%; Effective: integration reduces 30%-70%; Invalid: integration reduces <30%.
The therapeutic effect of table 2 Chinese medicine composition of the present invention to anaphylaxis conjunctivitis
| Group | N | Effective | Effectively | Invalid | Total effective rate |
| Administration group | 45 | 24 * | 18 * | 3 | 93.3% * |
| Matched group | 45 | 15 | 9 | 11 | 75.6% |
With matched group comparison,
*p < 0.05
As can be seen from Table 2, Chinese medicine composition of the present invention is significantly better than cetirizine hydrochloride for the therapeutic effect of anaphylaxis conjunctivitis.
Claims (4)
1. treat the Chinese medicine composition of conjunctivitis for one kind, it is characterized in that being made by the raw material of following weight portion: 15 parts of Radix Scutellariaes, 6 parts of Flos Loniceraes, 10 parts of Radix Saposhnikoviaes, 10 parts of Herba Artemisiae Scopariaes, 10 parts of Rhizoma Chuanxiongs, 20 parts of Herba Taraxacis, 20 parts of Periostracum Cicadaes, 10 parts of Radix Gentianaes, 5 parts of the Radix Paeoniae Albas, 5 parts of Herba Menthaes, 10 parts, Radix Glycyrrhizae.
2. the Chinese medicine composition for the treatment of conjunctivitis as claimed in claim 1, is characterized in that described pharmaceutical composition is mixture, tablet or capsule.
3. the preparation method of the Chinese medicine composition for the treatment of conjunctivitis as claimed in claim 1, it is characterized in that comprising the following steps: get each medical material, add the water of 5-15 times of medical material gross weight, soak 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.05-1.25, this relative density is the testing result under 60 degrees Celsius, add ethanol to being 60-90%v/v containing alcohol amount, leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, to obtain final product.
4. the purposes of the Chinese medicine composition for the treatment of conjunctivitis as claimed in claim 1 or 2 in preparation treatment conjunctivitis medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210380257.5A CN102836228B (en) | 2012-10-10 | 2012-10-10 | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210380257.5A CN102836228B (en) | 2012-10-10 | 2012-10-10 | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102836228A CN102836228A (en) | 2012-12-26 |
| CN102836228B true CN102836228B (en) | 2014-06-25 |
Family
ID=47364131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210380257.5A Active CN102836228B (en) | 2012-10-10 | 2012-10-10 | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102836228B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110743B (en) * | 2013-03-08 | 2014-07-23 | 崔合芳 | Traditional Chinese medicine composition for treating or preventing neurasthenia and preparation method thereof |
| CN103251744A (en) * | 2013-04-06 | 2013-08-21 | 李彩萍 | Traditional Chinese medicine composition for treating keratitis and conjunctivitis |
| CN103505680B (en) * | 2013-08-31 | 2015-04-08 | 宋景戈 | Traditional Chinese medicine composition for treating acute conjunctivitis |
| CN104383275A (en) * | 2014-10-16 | 2015-03-04 | 宁波大学 | Chinese herbal preparation used for curing allergic conjunctivitis |
| CN104288626A (en) * | 2014-10-28 | 2015-01-21 | 青岛华仁技术孵化器有限公司 | Medicine for treating acute conjunctivitis |
| CN104887973A (en) * | 2015-07-04 | 2015-09-09 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating acute catarrhal conjunctivitis with cough |
| CN105267434A (en) * | 2015-10-27 | 2016-01-27 | 叶宗耀 | Traditional Chinese medicine composition for treating allergic conjunctivitis and preparation method of traditional Chinese medicine composition for treating allergic conjunctivitis |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850191A (en) * | 2006-03-14 | 2006-10-25 | 北京国丹药物技术开发有限公司 | Eye drops with capillary artemisia, cape jasmine and baikal skullcap root, and its preparing method |
| CN101168029A (en) * | 2007-11-06 | 2008-04-30 | 郭太平 | Method for manufacturing liver-smoothing, qi-regulating and detoxification capsule |
| CN101181365A (en) * | 2007-11-15 | 2008-05-21 | 王玉鑫 | Chinese medicine composition orally taken for curing tonsillitis |
| CN101879223A (en) * | 2009-05-05 | 2010-11-10 | 天津市圣世莱科技有限公司 | Chinese medicinal composition for treating livestock and poultry viral diseases and preparation method thereof |
| CN102366488A (en) * | 2011-09-28 | 2012-03-07 | 邓华伦 | Chinese herbal medicine for treating infectious conjunctivitis |
| CN102423349A (en) * | 2011-11-01 | 2012-04-25 | 文登市口腔医院米山路口腔诊所 | Traditional Chinese medicine for curing acute pinkeye |
| CN102688301A (en) * | 2012-05-31 | 2012-09-26 | 王亚明 | Traditional Chinese medicine lotion for treating acute conjunctivitis and preparation method thereof |
-
2012
- 2012-10-10 CN CN201210380257.5A patent/CN102836228B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850191A (en) * | 2006-03-14 | 2006-10-25 | 北京国丹药物技术开发有限公司 | Eye drops with capillary artemisia, cape jasmine and baikal skullcap root, and its preparing method |
| CN101168029A (en) * | 2007-11-06 | 2008-04-30 | 郭太平 | Method for manufacturing liver-smoothing, qi-regulating and detoxification capsule |
| CN101181365A (en) * | 2007-11-15 | 2008-05-21 | 王玉鑫 | Chinese medicine composition orally taken for curing tonsillitis |
| CN101879223A (en) * | 2009-05-05 | 2010-11-10 | 天津市圣世莱科技有限公司 | Chinese medicinal composition for treating livestock and poultry viral diseases and preparation method thereof |
| CN102366488A (en) * | 2011-09-28 | 2012-03-07 | 邓华伦 | Chinese herbal medicine for treating infectious conjunctivitis |
| CN102423349A (en) * | 2011-11-01 | 2012-04-25 | 文登市口腔医院米山路口腔诊所 | Traditional Chinese medicine for curing acute pinkeye |
| CN102688301A (en) * | 2012-05-31 | 2012-09-26 | 王亚明 | Traditional Chinese medicine lotion for treating acute conjunctivitis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102836228A (en) | 2012-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102836228B (en) | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof | |
| CN102198236B (en) | Chinese medicine composition for treating acute sinusitis and preparation method thereof | |
| CN103585433B (en) | Traditional Chinese medicine composition for treating oral ulcer | |
| CN102205026B (en) | Chinese medicinal composition for treating children chronic sinusitis and preparation method thereof | |
| CN104799115A (en) | Chicken compound feed and preparation method thereof | |
| CN105560372A (en) | Traditional Chinese medicine spray for treating rhinitis and preparation method thereof | |
| CN103182023A (en) | Medicine for treating chronic pharyngitis and preparation method thereof | |
| CN105213941A (en) | A kind of Chinese medicine composition being used for the treatment of infantile diarrhea and preparation method thereof | |
| CN104013846A (en) | Traditional Chinese medicine composition for treating dental ulcer and application thereof | |
| CN103263531B (en) | Chinese medicine composition for treating prosopalgia and preparation method thereof | |
| CN102614413B (en) | Chinese medicinal composition for treating sinusitis in children and preparation method thereof | |
| CN104983968B (en) | Antipyretic traditional Chinese medicine composition and preparation method thereof | |
| CN103893593B (en) | Pharmaceutical composition with effects of clearing away heat and toxic materials, resisting inflammations and boosting immunity | |
| CN105535495A (en) | Chinese medicinal composition for treating esophageal cancer by reinforcing vital essence and strengthening primordial qi and preparation method | |
| CN114177231B (en) | Antipyretic pharmaceutical composition, antipyretic gel and preparation method | |
| CN105381310A (en) | Traditional Chinese medicine preparation for treating phthisis and preparing method thereof | |
| CN104984292A (en) | Medicine composition for treating mycoplasmal pneumonia and preparation method thereof | |
| CN104474148A (en) | Traditional Chinese medicine composition used for treating dermatomycosis and preparation method thereof | |
| CN102940753B (en) | Pills for treating glaucoma and preparation method | |
| CN104352794A (en) | Traditional Chinese medicine preparation for treating lung yin deficiency type xerophthalmia | |
| CN104274750A (en) | Traditional Chinese medicinal composition for treating acute bronchitis and upper respiratory infection | |
| CN104173830A (en) | Medicament for reconciling interior syndromes and relieving exterior syndromes for high fever of cold in winter and preparation method thereof | |
| CN103110737B (en) | Traditional Chinese medicine composition for treating gynecologic inflammation and preparation method thereof | |
| CN107970381A (en) | A kind of Xuancheng's pawpaw tea of resolving sputum and its preparation method and application | |
| CN113101331B (en) | Thyme herb tea and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: CUI HEFANG Free format text: FORMER OWNER: CHEN XINGWANG Effective date: 20130508 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 276017 LINYI, SHANDONG PROVINCE TO: 266200 QINGDAO, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20130508 Address after: 266200 Jimo, Shandong, the Yellow River Road No. two, No. 182, No. Applicant after: Cui Hefang Address before: Three village Chu Dun Zhen 276017 Shandong province Linyi city Luozhuang District No. 89 group Applicant before: Chen Xingwang |
|
| ASS | Succession or assignment of patent right |
Owner name: BINZHOU MEDICAL UNIVERSITY HOSPITAL Free format text: FORMER OWNER: CUI HEFANG Effective date: 20140505 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Weiguo Inventor after: Gong Yuerong Inventor before: Li Weiguo Inventor before: Gong Yuerong |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266200 QINGDAO, SHANDONG PROVINCE TO: 256600 BINZHOU, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20140505 Address after: 256600 No. two, No. 661, the Yellow River Road, Shandong, Binzhou Applicant after: Binzhou Medical University Hospital Address before: 266200 Jimo, Shandong, the Yellow River Road No. two, No. 182, No. Applicant before: Cui Hefang |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: CUI HEFANG Free format text: FORMER OWNER: BINZHOU MEDICAL UNIVERSITY HOSPITAL Effective date: 20140728 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 256600 BINZHOU, SHANDONG PROVINCE TO: 266200 QINGDAO, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140728 Address after: 266200 Jimo, Shandong, the Yellow River Road No. two, No. 182, No. Patentee after: Cui Hefang Address before: 256600 No. two, No. 661, the Yellow River Road, Shandong, Binzhou Patentee before: Binzhou Medical University Hospital |
|
| ASS | Succession or assignment of patent right |
Owner name: NANTONG HONGCI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CUI HEFANG Effective date: 20140829 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266200 QINGDAO, SHANDONG PROVINCE TO: 226200 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140829 Address after: 226200 Qidong chemical industry park, Jiangsu, Nantong Patentee after: NANTONG HONGCI PHARMACEUTICAL CO., LTD. Address before: 266200 Jimo, Shandong, the Yellow River Road No. two, No. 182, No. Patentee before: Cui Hefang |